Breaking News

Addex, Merck to Develop Schizophrenia Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Addex Pharmaceuticals has entered an exclusive worldwide license agreement with Merck to develop ADX63365, an oral drug candidate for the potential treatment of schizophrenia and other undisclosed indications. ADX63365, currently in preclinical development, is a positive allosteric modulator (PAM)—a new class of therapeutic agents—that targets the metabotropic glutamate receptor 5 (mGluR5), which is believed to be an important target for the treatment of schizophrenia and other conditions. The a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters